ArticleEJIFCC2026
Autoantibody Profiles and Clinical Correlations in Systemic Sclerosis: A Cross-Sectional Study.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic sclerosis (SSc) is a rare autoimmune disease marked by immune dysregulation, vascular injury, and fibrosis. Antinuclear antibodies (ANA) are pivotal for diagnosis and prognosis, yet Indian data remain scarce. This study assessed ANA patterns and autoantibody profiles in SSc and their clinical relevance. Methods: A cross-sectional study was conducted in the Department of Dermatology, AIIMS Patna, from September 2022 to September 2023. Eighty-five patients fulfilling ACR/EULAR criteria for SSc were enrolled. Clinical features were documented using a structured proforma, and patients were classified into diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subsets. ANA screening was performed by indirect immunofluorescence (IIF) on HEp2 cells, followed by autoantibody profiling with line immunoassay (LIA). Statistical analyses were performed using JAMOVI v2.3.28, with p<0.05 considered significant. Results: Of 85 patients, 70 (82.4%) were female (ratio of 5:1), with a mean age of 34.7 ± 10.7 years. dcSSc accounted for 55.3%. Common manifestations included arthralgia (69.4%), respiratory symptoms (68.2%), and interstitial lung disease (ILD) (64.1%). Homogeneous ANA was the predominant IIF pattern (41.2%), followed by centromere (10.6%) and speckled (8.2%). LIA revealed anti-Scl70 as the most frequent autoantibody (58.3%), significantly associated with ILD and Raynaud's phenomenon. Anti-U1 snRNP and anti-PMScl antibodies correlated with musculoskeletal involvement. Conclusion: SSc in this cohort showed female predominance with frequent arthralgia and respiratory symptoms. Anti-Scl-70 antibodies were most common, strongly linked to diffuse disease and ILD. ANA profiling provides disease characterization in Indian SSc.
Indexed as
Identifiers
42699467PMC13543460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.